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Abstract
Background: Breakdown of the gut mucosal barrier during chronic HIV infection allows translocation of bacterial products
such as lipopolysaccharides (LPS) from the gut into the circulation. Microbial translocation also occurs in inflammatory
bowel disease (IBD). IBD serological markers are useful in the diagnosis of IBD and to differentiate between Crohn’s disease
(CD) and ulcerative colitis (UC). Here, we evaluate detection of IBD serological markers in HIV-infected patients with
advanced disease and their relationship to HIV disease markers.
Methods: IBD serological markers (ASCA, pANCA, anti-OmpC, and anti-CBir1) were measured by ELISA in plasma from AIDS
patients (n=26) with low CD4 counts (,300 cells/ml) and high plasma LPS levels, and results correlated with clinical data.
For meta-analysis, relevant data were abstracted from 20 articles.
Results: IBD serological markers were detected in approximately 65% of AIDS patients with evidence of microbial
translocation. An antibody pattern consistent with IBD was detected in 46%; of these, 75% had a CD-like pattern. Meta-
analysis of data from 20 published studies on IBD serological markers in CD, UC, and non-IBD control subjects indicated that
IBD serological markers are detected more frequently in AIDS patients than in non-IBD disease controls and healthy
controls, but less frequently than in CD patients. There was no association between IBD serological markers and HIV disease
markers (plasma viral load and CD4 counts) in the study cohort.
Conclusions: IBD serological markers may provide a non-invasive approach to monitor HIV-related inflammatory gut
disease. Further studies to investigate their clinical significance in HIV-infected individuals are warranted.
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Introduction
CD4 T-cells in gut-associated lymphoid tissue (GALT) are
primary target cells of HIV, and GALT is an important site for
HIV replication and pathogenesis [1–4]. Significant CD4 T cell
loss occurs in the gastrointestinal tract within the first few weeks of
infection [5–7]. Later on, during chronic HIV infection, loss of
GALT integrity and breaching of the gut mucosal barrier leads to
microbial translocation [8–10], which is evidenced by the release
of microbial products such as bacterial endotoxins (lipopolysac-
charides (LPS), a component of gram negative bacteria) into the
circulation (endotoxemia) [11]. Microbial translocation from a
leaky gut may contribute to immune activation during chronic
HIV infection [11–15]. Elevated levels of plasma LPS and
bacterial 16S rDNA have been used to measure translocation of
microbial products from the gastrointestinal tract [11,16].
Microbial translocation is also a noted feature in inflammatory
bowel disease (IBD) [17–20]. IBD comprises a group of intestinal
diseases characterized by chronic inflammation of the bowel;
Crohn’s disease (CD) and ulcerative colitis (UC) are the common
clinical subtypes of IBD. The intestinal bacterial flora triggers and
drives an aberrant immune response in a genetically susceptible
host, resulting in chronic inflammation of the gut [21,22]. Low
level endotoxemia has pathogenic significance in IBD; it occurs in
31%–48% of CD patients and 17%–28% of UC patients [18,23],
with a higher incidence in patients with active IBD (94% in CD,
88% in UC) [19].
The role of enteric microflora in IBD pathophysiology is
highlighted by the presence of antibody reactivity to microbial
antigens. These serological markers can be helpful to distinguish
between CD and UC as well as aiding in the diagnosis of IBD
along with clinical history, endoscopy, and physical examination
[24]. The currently available IBD serological markers are: ASCA
(anti-Saccharomyces cerevisiae antibody) [25–31], pANCA (perinuclear
anti-neutrophil antibody) [25–30,32], and anti-OmpC (antibody
against outer membrane porin C of E.coli) [28,33–37]. ASCA,
which is directed against a mannose epitope in the phosphopepti-
domannan of the Saccharomyces cerevisiae cell wall [30–32], is
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for detection of ASCA antibodies in CD are 50%–70% and 80%–
90%, respectively [25,27,29,30,32,37,42,43]. pANCA is an
antibody directed against cytoplasmic constituents of neutrophils
with a perinuclear staining pattern [25,44,45]. pANCA is detected
in 40%–80% of UC patients, but also in 6%–20% of CD patients
who can be classified as having a UC-like phenotype
[30,32,37,46,47], with sensitivity and specificity between 55%–
70% and 80%–95% in UC patients [27,29,30,32,37,43,45–47].
Anti-OmpC antibodies are detected in 40%–55% of CD patients
[25,48–51], with sensitivity and specificity ranging between 20%–
55% and 75%–95%, respectively [25,34,37,50,52]. Anti-CBir1
(antibodies against bacterial flagellin) is a new serological marker
associated with IBD [28,35,53-58]. CBir1 flagellin is an immuno-
dominant and colitogenic antigen of enteric microbial flora [58].
Anti-CBir1 is detected in approximately 50% of CD patients
[28,35,53,55–58], and is independently associated with compli-
cated CD [25,33,35,59].
A number of parallels are observed between HIV and IBD in
terms of gut disease [60–62]. Small intestinal villous atrophy and
enterocyte defects have been described in HIV-infected patients.
Because these defects usually occur in the absence of enteric
pathogens, the term HIV enteropathy has been used [60,62,63].
Characteristic features of HIV enteropathy are diarrhea, gastro-
intestinal inflammation, increased intestinal permeability, and
decreased mucosal repair and regeneration [1,2,60,64]. Previous
studies reported infrequent cases of IBD in HIV-infected patients
[61,65–67]. To our knowledge, however, no reports have
examined the prevalence of ASCA, OmpC, and CBir1 antibodies
in HIV infection.
We previously demonstrated that elevated circulating LPS levels
correlate with monocyte activation during HIV infection, and may
thereby contribute to chronic immune activation [12]. In the
present study, we evaluated detection of IBD serological markers
in AIDS patients with low CD4 counts (,300 cells/ml) and high
plasma LPS levels. We detected IBD serological antibodies in
approximately 65% of subjects. A serological pattern consistent
with IBD was detected in 46% of AIDS patients; of these, 75%
showed a CD-like pattern, while 25% had a UC pattern. IBD
serological markers may provide a non-invasive approach to
monitor HIV-related gut disease. Further studies to determine
their prognostic significance in HIV-infected individuals are
warranted.
Methods
Subjects
AIDS patients with CD4 counts ,300 cells/ml were recruited at
the Lemuel Shattuck Hospital (n=20), or at 3 sites in the National
NeuroAIDS Tissue Consortium (NNTC) (Manhattan HIV Brain
Bank, National Neurological AIDS Bank, Texas NeuroAIDS
Research Center) (n=6) with written informed consent and IRB
approval at each study site. Patients with active bacterial or
opportunistic infections were excluded. There was no available
radiographic, endoscopic, or histopathologic data for the gut. All
plasma samples were stored at 280uC until analyzed.
Laboratory assays
Frozen plasma samples were shipped on dry ice to Prometheus
Laboratories (San Diego, CA) and analyzed in a blinded fashion;
Prometheus staff did not have access to clinical information except
for HIV/HCV status. Prometheus IBD Serology 7 is the most
comprehensive IBD test available, utilizing several proprietary
markers and incorporating computer-based Smart Diagnostic
Algorithm pattern recognition technology to aid in the diagnosis of
IBD as well as differentiate between CD and UC. Prometheus IBD
Serology 7 tests include the following assays: ASCA IgA and IgG,
anti-OmpC IgA antibodies, IgG anti-CBir1, and pANCA
autoantibody by ELISA, and immunofluorescence assay (IFA) to
determine the perinuclear pattern of neutrophils and DNAse
sensitivity. The reference cut-off for each assay was defined by
Prometheus laboratories (ASCA IgA ,20 EU/ml, ASCA IgG
,40 EU/ml, anti-OmpC ,16.5 EU/ml, anti-CBir1 ,21 EU/
ml, and pANCA autoantibody ,12.1 EU/ml). Positive samples
showing patterns consistent with IBD were reported based on
analysis by Prometheus Smart Diagnostic Algorithm Technology.
Quantification of cytokines and chemokines
A multiplex immunoassay (Bio-source 25-plex Human Cytokine
Assay; Invitrogen., CA, USA), consisting of fluorescent micro-
spheres conjugated with a monoclonal antibody specific for a
target protein, was used according to the manufacturer’s
instructions to measure levels of the following cytokines IL-1b,
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, IFN-
a, IFNc, TNF-a granulocyte-monocyte colony stimulating factor
(GM-CSF), monocyte chemoattractive protein (MCP-1/CCL2),
macrophage inflammatory protein (MIP-1b/MIP-1a), IP-10,
MIG, Eotaxin and RANTES. Briefly, plasma was diluted 1:2
and incubated with antibody-coupled beads. Complexes were
washed and then incubated with biotinylated detection antibody
followed by streptavidin-phycoerythrin prior to assessing titers of
cytokine concentration. Recombinant cytokines were used to
establish standard curves. Cytokine levels were determined using a
multiplex array reader from Luminex
TM Instrumentation System
(Bio-Plex Workstation from Bio-Rad Laboratories, USA). Analyte
concentration was calculated using Bioplex Manager Software.
Statistical analysis
Data were analyzed using the Mann-Whitney U test and
Spearman rank correlation coefficient. Differences were consid-
ered significant at p,0.05.
Results
IBD serological markers in AIDS
To investigate the frequency and pattern of IBD serological
markers in AIDS patients, we used the Prometheus IBD Serology
7 test to detect IBD serological markers in plasma samples.
Subjects were selected from a larger cohort of 119 AIDS subjects
with CD4 counts ,300 cells/ml described in a previous study [12]
on the basis of high plasma LPS above the median value for AIDS
patients in the study cohort (.80 pg/ml) levels; LPS levels were
determined in the previous study using the Diazo-coupled Limulus
amebocyte lysate (LAL) assay. The study cohort consisted of 26
AIDS patients with relatively high plasma viral loads (median
10,935 copies/ml, range ,50–2,210,000) and low CD4 counts
(median 80 cells/ml, range 3–261), together with a high frequency
of intravenous drug abuse (IVDU) (65%), HCV co-infection
(50%), and HIV-associated dementia (HAD) (50%). Eleven
subjects were both IVDU and HCV positive. Demographic and
clinical characteristics of the study cohort are shown in Table 1.
All subjects were on HAART, but only 23% were virologically
suppressed (,400 plasma HIV RNA copies/ml).
In the study cohort (n=26), ASCA IgA, pANCA, and anti-
OmpC were detected in 31% (8/26), while ASCA IgG and anti-
CBir1 were detected in 15% (4/26) (Table 2). Prometheus
laboratories classified subjects as having a CD- or UC-like pattern
according to Smart Diagnostic Algorithm Technology. According
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consistent with IBD, with 75% (9/12) having a CD-like pattern
and 25% (3/12) having a UC-like pattern. In subjects with a
positive IBD pattern, ASCA IgA and IgG antibodies were detected
in 50% and 33%, while anti-OmpC, anti-CBir1, and pANCA
were detected in 67%, 33%, and 42%, respectively (Table 2).
Three patients with a pANCA (+) anti-OmpC (+) pattern and 1
with a pANCA (+) anti-CBir1 (+) pattern (n=1) could also be
classified as having a pattern consistent with UC-like CD
[25,29,48,68,69,70]. Thus, IBD serological markers were detected
in approximately 65% of AIDS patients with high plasma LPS
levels, with 46% having an IBD-like pattern and the majority of
these having a CD-like pattern.
IBD serological markers in subgroups with IV heroin use,
HCV co-infection, or HIV-associated dementia (HAD)
Previous studies reported that AIDS patients with heroin
IVDU, HCV co-infection or HAD have higher plasma LPS levels
compared to respective control groups [12,71]. Furthermore,
substance abuse and HCV co-infection are associated with an
increased incidence of bacterial infections [72]. We therefore
examined the pattern of ASCA, pANCA, anti-OmpC, and anti-
CBir1 in AIDS patients classified according to these subgroups
(Table 2 and data not shown). There was no significant difference
in the frequency or magnitude of IBD serological markers between
IVDU heroin users compared to patients with no substance abuse,
HCV-positive compared to HCV-negative subjects, or HAD
compared to non-HAD subjects (Table 2 and data not shown).
Thus, there was no difference in magnitude or frequency of IBD
serological markers in these clinical subgroups.
Higher ASCA IgG, anti-OmpC, and anti-CBir1 levels but
similar plasma viral load and CD4 counts in AIDS patients
with IBD-like serological pattern
Higher levels of ASCA IgG (median 31.4 EU/ml, range 12–120
compared to 12 EU/ml, 12–27.9, p=0.027), anti-OmpC
(25.9 EU/ml, 4.7–111, compared to 7.1 EU/ml, 1–15.3,
p=0.005), and anti-CBir1 (18.6 EU/ml, 8–37.7, compared to
9.1 EU/ml, 5.5–15.6, p=0.001) were detected in subjects with a
positive IBD pattern as compared to those with a negative pattern
(Table 3 and Figure S1). In contrast, there was no significant
difference in ASCA IgA and pANCA antibody levels between
these two groups (p=0.135 and p=0.540). We then investigated
the relationship of IBD serological markers to HIV disease
markers, plasma LPS, and EndoCAb levels. HIV RNA levels,
CD4 cell counts, plasma sCD14, plasma LPS, and IgM EndoCAb
levels were similar in the 2 groups (Table 3). Furthermore, there
were no significant correlations (Spearman correlation) between
levels of individual IBD serological markers and HIV RNA levels,
CD4 cell counts, plasma sCD14, or plasma LPS levels (data not
shown). Thus, we found no association between IBD serological
markers and HIV disease markers or plasma LPS levels in the
study cohort.
No association of IBD serological markers with plasma
cytokines and chemokines in AIDS patients
In IBD, the dysregulated inflammatory response is associated
with upregulation of mucosal and systemic levels of cytokines (i.e.,
IL-1, IL-6, IL-8, IL-12, and TNF) [73]. We used a multiplex assay
to measure levels of 25 cytokines and chemokines in plasma
samples from 20 AIDS patients in the study cohort and explore
their relationship to individual IBD serological markers. We
detected higher levels of IL-2R, CXCL9, CXCL10, CCL2, and
IL-6 (p=0.001, 0.0003, 0.0002, 0.017, and 0.0005, respectively) in
plasma of AIDS patients compared to healthy uninfected controls
(data not shown). No significant differences in cytokine/chemokine
levels were seen when AIDS subjects were grouped according to
positive (n=9) versus negative IBD (n=11) pattern (data not
shown). Only IL-10 showed a trend towards significance (median
7.26 (range 0–41.94 pg/ml) versus 2.14 (0–8 pg/ml) respectively,
p=0.087, data not shown), with higher levels in patients with a
positive IBD pattern. We then examined the association of
individual IBD serological markers with levels of IL-1b, IL-2R, IL-
6, IL-10, IL-17, IP-10, IFNc, TNF, MIP-1a, MIP-1b, and MCP-
1, and found a positive correlation only between anti-CBir1
antibody and IL-6 (r=0.447, p=0.048, Figure S2). Together with
previous studies demonstrating that CBir1 antigen can induce IL-6
and other proinflammatory cytokines [56,58], this finding raises
the possibility that translocation of flagellin into the circulation
may be a factor that contributes to immune activation in AIDS.
Magnitude of IBD serological antibody response in AIDS
Previous data suggested that the magnitude of antibody
responses to microbial antigens is associated with increased risk
Table 1. Demographic and clinical characteristics of HIV
patients in the study cohort (n=26).
Age (years)
Median (range) 45 (32–63)
Gender
Male 19 (73%)
Female 7 (27%)
Race/ethnicity
African American 6 (23%)
Caucasian 12 (46%)
Hispanic 8 (31%)
Plasma HIV RNA (copies/ml)
Mean 6 SD 215,7186590,409
Median (range) 10,935 (,50–2,210,000)
.400 copies/ml 18 (69%)
,400 copies/ml 6 (23%)
Unknown 2 (8%)
CD4 T Cell Count (cells/ml)
Mean 6 SD 98.6684.4
Median (range) 80 (3–261)
Plasma LPS (pg/ml)
Mean6 SD 128.07656.18
Median (range) 109 (82.5–279.6)
HCV Co-infection
Negative 7 (27%)
Positive 13 (50%)
Unknown 6 (23%)
Substance abuse
No IVDU 9 (35%)
Heroin IVDU 8 (31%)
Heroin and Cocaine IVDU 5 (19%)
Cocaine IVDU 4 (15%)
doi:10.1371/journal.pone.0015533.t001
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to HIV disease progression by counting the number of positive
antibodies (ASCA, pANCA, anti-OmpC, and anti-CBir1) and
scoring these from 0–3 (Table 4). None of the subjects showed a
positive response for all 4 antibodies; 26.9% (7/26) had a score of 1,
30.7% (8/26) had a score of 2, 7.6% (2/26) had a score of 3, and
34.6% (9/26) had a score of zero. Forty-two percent (6/14) of subjects
with CD4 T - cell counts ,100cells/ml versus 27% (3/11) with .100
cells/ml had antibody responses to 2 antigens, but this difference did
not reach statistical significance (p=0.676). Subjects grouped
according to HIV RNA levels .10,000 versus ,10,000 copies/ml,
heroin use versus no heroin use, HAD versus non-HAD, or LPS .
median value of 109 pg/ml versus ,109 pg/ml had no difference in
the magnitude of antibody response. Thus, the magnitude of IBD
serological antibody responses was not associated with HIV disease
markers, high LPS levels, or clinical subgroups in the study cohort.
Table 2. Profile of inflammatory bowel disease (IBD) serological markers in AIDS subjects.
HIV positive subjects
n=26
n( % )
Smart Algorithm positive
subjects
n=12
n( % )
Heroin IVDU subjects
n=13
n( % )
HCV positive subjects
n=13
n( % )
ASCA IgA 8 (31) 6 (50) 4 (31) 5 (38)
ASCA IgG 4 (15) 4 (33) 2 (15) 2 (15)
Anti-OmpC IgA 8 (31) 8 (67) 4 (31) 3 (23)
Anti-CBir1 4 (15) 4 (33) 2 (15) 2 (15)
NSNA (IBD Specific pANCA)
pANCA Autoantibody 8 (31) 5 (42) 5 (38) 2 (15)
IFA Perinuclear Pattern 5 (19) 4 (33) 2 (15) 2 (15)
DNAse Sensitivity 5 (19) 4 (33) 2 (15) 2 (15)
Crohn’s- like pattern* 9 (35) 9 (75) 5 (38) 4 (31)
UC-like pattern* 3 (11) 3 (25) 1(7.6) 1 (7.6)
UC-like Crohn’s pattern
ANCA (+) OmpC (+)** 3 (11) 3 (11) 1 (7.6) 1 (7.6)
ANCA (+) CBir (+)*** 1 (3.8) 1 (3.8) 1 (7.6) 0 (0)
Abbreviations: Heroin IVDU - Intravenous drug users using heroin, or heroin and cocaine; ASCA IgA/Ig - Anti-Saccharomyces cerevisiae antibodies; Anti-OmpC IgA- Anti-
Outer membrane porin C on E.coli; Anti-CBir1- recognizes bacterial flagellin antigen associated with IBD; pANCA autontibody - IBD- specific pANCA autoantibody (NSNA,
Neutrophil-specific nuclear autoantibody);
*Based on Prometheus Smart Algorithm;
**patients with UC-like pattern according to Smart Algorithm also classified as having a UC-like CD pattern;
***One patient with CD-like pattern according to Prometheus Smart Algorithm also classified as having UC-like CD pattern.
doi:10.1371/journal.pone.0015533.t002
Table 3. Clinical and serological profile in AIDS subjects having a serological pattern consistent with IBD versus not consistent
with IBD.
Pattern consistent with IBD
**
(n=12)
Pattern not consistent with IBD
**
(n=14) p-value
Age (years) 45 44 0.149
Plasma HIV RNA (copies/ml) 9,725 10,935 0.665
CD4 cell count (cells/ml) 84 66 0.956
Plasma sCD14 (mg/ml) 2.5 2.6 0.897
Plasma LPS (pg/ml) 121 105 0.207
Plasma EndoCAb (MMU/ml) 57 75 0.738
ASCA IgA (EU/ml) 19.7 12 0.135
ASCA IgG (EU/ml) 31.4 12 0.027*
Anti-OmpC IgA (EU/ml) 25.9 7.1 0.005*
Anti- CBir1 (EU/ml) 18.6 9.1 0.001*
pANCA AutoAb (EU/ml) 12.1 12.1 0.540
Abbreviations: IBD - Inflammatory bowel disease;
**numbers represent median values; Statistical analysis was performed using Mann-Whitney test,
*p,0.05 statistically significant; ASCA IgA/IgG- Anti-Saccharomyces cerevisiae antibodies; Anti-OmpC IgA- Anti-Outer membrane porin C on E.coli; Anti-CBir1-
recognizes bacterial flagellin antigen associated with IBD; pANCA autoantibody-
IBD-specific pANCA autoantibody (NSNA, Neutrophil-specific nuclear autoantibody).
doi:10.1371/journal.pone.0015533.t003
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In this study, we examined IBD serological markers in AIDS
patients with high plasma LPS levels and detected an IBD-like
serological pattern in 46%. Among subjects with a positive IBD
pattern, 75% had a CD-like pattern and 25% had a UC-like
pattern. The association of pANCA with CD markers has been
described as a UC-like Crohn’s pattern [25,29,43,69,70]. Based on
this classification, 15% of the study cohort had a UC-like CD
pattern. These findings are consistent with the frequent occurrence
of HIV-related gut disease involving the small and large intestine
in AIDS patients [1,2,3,4]. Antibodies to microbial antigens
(ASCA IgG, anti-OmpC, and anti-CBir1) were detected at higher
levels in AIDS patients with compared to those without an IBD
serological pattern. These findings together with the detection IBD
serological markers in approximately 65% of AIDS patients with
high plasma LPS suggest that IBD markers, in particular ASCA,
anti-OmpC, and anti-CBir1, may provide a non-invasive
approach to monitor HIV-related inflammatory gut disease, and
possibly therapeutic responses.
Our original hypothesis was that high plasma LPS levels or HIV
disease markers would be associated with detection of IBD
serological markers. However, we found no difference in LPS
levels between AIDS subjects with versus without an IBD-like
serological pattern, and no association between the frequency or
magnitude of IBD serological markers and HIV RNA levels, CD4
cell counts, plasma sCD14 or LPS levels. We found a higher
magnitude of antibody responses to 2 antigens in AIDS patients
with low CD4 counts or high viral loads as compared to other
clinical subgroups, but this difference did not reach statistical
significance. pANCA antibodies were previously detected in 18%
to 41.9% of patients with symptomatic HIV infection [74,75,76],
and in 20% of heroin users with systemic complications
irrespective of HIV infection [77]. Consistent with these findings,
we detected pANCA in 31% of AIDS patients and 38% of heroin
users. Nonetheless, detection or levels of pANCA did not
discriminate between subgroups classified according to positive
IBD pattern, HIV disease markers, or IV heroin use. Together,
these unexpected findings could reflect differences in gut
commensalism, other host factors that affect gut homeostasis, or
limitations of our study such as the small sample size, cross-
sectional design, or selection of subjects with high LPS levels.
Alternatively, the severity of HIV- related gut disease may not be
detected by serological measurements of IBD markers or HIV
disease biomarkers. We also cannot exclude the possibility that the
absence of antibody responses to microbial antigens in 35% (9/26)
of AIDS patients with high LPS levels reflects weakened humoral
immune responses. Another limitation of our study is the lack of
endoscopy or gut pathology data for the study cohort. Viazis et al
[66] examined IBD outcomes in HIV-infected subjects who had
an IBD diagnosis and found that these patients have a better
disease course with lower probability of IBD relapse as compared
to HIV-negative IBD patients. This was attributed to lower CD4
T-cell counts in HIV-infected individuals suppressing disease
activity in CD. If true, low CD4 counts in our study cohort might
influence relationships between HIV disease markers or LPS levels
and IBD serological antibodies. The Th17 subset of CD4+ T-cells
play an important role in the pathogenesis of IBD; HIV
preferentially infects and depletes these cells in GALT, which
may also help to explain the better disease course observed in
patients with an IBD diagnosis who are HIV-positive compared to
those who are HIV-negative. Larger prospective studies are
needed to determine the clinical significance of IBD serological
markers in HIV-infected patients and their relationship to HIV-
related gut disease.
To assess the diagnostic precision of IBD serological antibodies
and their ability to distinguish between CD, UC, inflammatory
and non-inflammatory non-IBD disease subjects, and healthy
controls, we performed meta-analysis of serological data from 20
published studies [25,27–30,33–35,37,42,49,52,53,55,57,58,78–
81]. Extensive meta-analysis was previously reported for ASCA
and pANCA antibodies [43]. To our knowledge, however,
the present study is the first meta-analysis for all available
IBD serological markers. Consistent with previous reports
[25,27,29,30,34,37,79,81], our meta-analysis demonstrated that
the prevalence of ASCA IgA/IgG was 45% in CD subjects as
compared to 7.9% and 3.7% in non-IBD and healthy controls,
respectively, and pANCA was prevalent in 42.4% of UC subjects
(Table 5) [26,27,29,32,37,44,82]. Anti-OmpC and anti-CBir1
were prevalent in 29.4% and 55.2% of CD subjects, respectively,
compared to 17.6% and 25.5% in non-IBD disease controls, and
10.7% and 6.3% in healthy controls. A separate meta-analysis of
10 published studies that used Prometheus Laboratories IBD
Serological Markers (Table S1) demonstrated similar findings,
with ASCA, anti-OmpC, and anti-CBir1 more prevalent in CD
(48.5%, 32.2%, and 55.8%, respectively), pANCA more prevalent
in UC (67.9%), and ASCA, pANCA, and anti-OmpC prevalent in
Table 4. Clinical characteristics of AIDS patients in relation to the magnitude of IBD serological antibody response.
Subjects
Number of IBD serological antibodies
n( % )
01 2 3
AIDS patients (n=26) 9 (34.6) 7 (26.9) 8 (30.7) 2 (7.6)
CD4 ,100 cells/ml (n=14) 4 (28.5) 3 (21.4) 6 (42.8) 1 (7.1)
Plasma HIV RNA .10,000 HIV RNA copies/ml (n=12) 3 (25.0) 3 (25.0) 5 (41.6) 1 (8.3)
LPS .109 pg/ml* (n=13) 4 (30.7) 4 (30.7) 4 (30.7) 1 (7.6)
Heroin IVDU (n=13) 3 (23.0) 6 (46.1) 3 (23.0) 1 (7.6)
HAD (n=13) 4 (30.7) 4 (30.7) 4 (30.7) 1 (7.6)
Abbreviations used: HAD- HIV-associated dementia; Heroin IVDU- heroin intravenous drug users; LPS- Lipopolysaccharide;
Antibodies tested- ASCA IgA/IgG- Anti-Saccharomyces cerevisiae antibodies; Anti-OmpC IgA- Anti-Outer membrane porin C on E.coli;
Anti-CBir1- recognizes bacterial flagellin antigen associated with IBD; pANCA autoantiody- IBD-specific pANCA autoantibody (NSNA, Neutrophil-specific nuclear
autoantibody);
*represents cut-off above the median value for the study cohort.
doi:10.1371/journal.pone.0015533.t004
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PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e155331.6%–6.3% of non-IBD disease controls and 3.9%–9.9% of
healthy controls (Table S1). We detected ASCA, anti-OmpC, and
anti-CBir1 in 15%–31% of AIDS patients with high LPS levels
compared to 29.4%–55.2% in CD, 7.9%–25.5% in non-IBD
disease controls, and 3.7%–0.7% in healthy controls. Thus, IBD
serological markers were detected more frequently in AIDS
patients than in non-IBD disease controls or healthy subjects, but
less frequently than in CD patients.
IBD serological markers alone are not recommended for
diagnosis and monitoring of IBD because they are not robust
enough for routine use [50,83]. Moreover, prediction of IBD using
Smart Diagnostic Algorithm Technology has not been published
in peer-reviewed journals and test validation was done using only
healthy controls [83]. To our knowledge, there are no published
prospective studies on IBD serological markers in predicting
disease course in UC or CD. As such, prospective studies are
needed to determine their prognostic significance. Nonetheless,
our meta-analysis highlights the utility of IBD serological markers
in discriminating between CD, UC, non-IBD controls, and
healthy controls, and their potential use for further studies of gut
disease in HIV infection.
Several cytokines with proinflammatory activities (IL-1, IL-6,
IL-8, IL-12, and TNF-a) are upregulated in IBD, and are likely to
play an important role in clinical and immunopathological
manifestations of the disease [56,73]. Plasma IL-10 concentrations
are elevated in subjects with active CD and UC [84] or with UC
[85]. Similarly, higher levels of IL-10 in AIDS patients with
compared to those without an IBD-like pattern were suggested by
a trend towards significance in the present study. Higher levels of
IL-6 [56,73] and negative correlation between IL-6 and anti-
CBir1 were previously reported in CD subjects [56]. In contrast,
we found a positive correlation between IL-6 and anti-CBir1 in
AIDS patients. These findings suggest complex relationships
between antibody responses to CBir1 antigen and IL-6 induction,
and raise the possibility that translocation of flagellin from the gut
into the circulation, or associated pathogenic processes, might
contribute to immune activation in chronic HIV infection.
Limitations of this study are its cross-sectional design and small
sample size, which may have decreased the power to detect
significant associations between IBD serological markers and HIV
disease markers. Another limitation is the narrow selection criteria
used to define the study cohort, limited to AIDS subjects with CD4
counts ,300 cells/ml and high plasma LPS levels. These narrow
selection criteria may in part explain our inability to detect a
significant difference in HIV disease markers, plasma LPS levels,
or plasma cytokine/chemokine levels between patients with and
without an IBD-like pattern. In view of these limitations, we
recognize the need for further studies to examine the detection of
IBD serological markers and frequency of an IBD-like pattern in
patients with acute or chronic HIV infection before progression to
AIDS and in relation to gut disease documented by endoscopic or
pathologic exam. Despite these limitations, this study opens the
door for new opportunities to explore and validate the detection of
IBD serological markers in peripheral blood samples as novel
markers of gut disease in HIV infection.
In summary, we detected at least one IBD serological marker in
approximately 65% of AIDS patients with high LPS levels, and an
IBD-like serological pattern in 46%. Detection of these markers,
particularly ASCA, anti-OmpC, and anti-CBir1, could provide a
potential non-invasive approach to monitor HIV-related gut
disease. Further studies are warranted to understand the clinical
significance of IBD serological markers in HIV infection and their
utility as tools for studies of HIV-related gut disease and
monitoring therapeutic responses.
Supporting Information
Figure S1 Differences in levels of IBD serological markers (A-
ASCA IgA, B- ASCA IgG, C - Anti-OmpC and D- Anti-CBir1) in
subjects with versus without IBD pattern are shown. Lines indicate
median levels for each group. Mann Whitney test was used to
assess the difference in antibody levels between the two groups,
*p,0.05 was considered statistically significant. (EPS)
Figure S2 IL-6 levels correlated positively with levels of anti-
CBir1 (n=20 AIDS patients, Spearman correlation). (EPS)
Table S1 Meta-analysis of 10 studies using Prometheus
laboratories IBD Serology 7 (DOC)
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Table 5. Meta-analysis of 20 studies using IBD serological markers.
Marker Number of studies Number of subjects Positive for antibodies n (%)
CD UC
Disease
ontrols
Healthy
ontrols CD UC
Disease
controls
Healthy
ontrols CD UC
Disease
Controls
Healthy
Controls
ASCA IgA/IgG* 15 9 6 6 4893 1026 455 1071 2206 (45) 110 (10.7) 36 (7.9) 40 (3.7)
ANCA 10 8 6 6 2424 826 381 871 352 (14) 351 (42.4) 54 (16) 23 (2.6)
Anti-OmpC 10 4 2 3 4116 448 176 401 1211 (29.4) 90 (20) 31 (17.6) 43 (10.7)
Anti-CBir1 6 2 2 2 2261 100 43 80 1249 (55.2) 11 (11) 11 (25.5) 5 (6.3)
CD- Crohn’s Disease; UC- Ulcerative colitis;
*- any one of the antibodies present; Disease controls include inflammatory and non-inflammatory non-IBD disease controls (n=633), including 264 non-IBD
inflammatory gut diseases (i.e., colitis, gastroenteritis, celiac disease, etc); 193 non-inflammatory gut diseases (i.e., abdominal pain, diarrhea, lactose intolerance, etc); 90
rheumatologic disorders, and 86 other (i.e., constipation, nausea, rectal bleeding, etc).
Themeta-analysisincludes19studieswithCDpatients[25,27,28,29,30,33,34,35,37,42,49,52,53,55,57,58,78,79,81],12withUCpatients[25,27,29,30,34,37,42,52,57,58,78,79,81],
10 with non-IBD disease controls [25,29,30,37,52,57,58,78,79,80,81], and 8 with healthy controls [25,27,29,30,34,42,57,58,81].
doi:10.1371/journal.pone.0015533.t005
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